TSO3 appoints new Vice President of Operations

Ticker: TSX – TOS
Shares Outstanding: 82,602,989

QUÉBEC CITY, April 13, 2015 /CNW Telbec/ - TSO₃ Inc. (TSX: TOS) ("TSO3" or the "Corporation"), an innovator in sterilization technology for medical devices in healthcare settings, announced today that Mr. Daniel Rivard is joining the Company as Vice President of Operations. Mr. Rivard will lead the Company's initiative to scale-up production and product development.

"A graduate of Laval University with a degree in mechanical engineering, Daniel is a seasoned executive having nearly two decades of hands-on experience in development, production and operations. During his career, Daniel has held Senior Management / Executive positions with Bombardier Inc., STERIS Canada, ORTHOFAB and GSK Biologicals.  In addition to his experience, Daniel brings his goal oriented, results driven leadership style," stated R.M. (Ric) Rumble, President and CEO. "All of us at TSO₃ are very pleased to see him on board," concluded Mr. Rumble.

"I am extremely excited about the opportunities that lay before TSO_3. I am eager to join the Company and contribute to the organization's success," stated Mr. Rivard.  

About the STERIZONE^® VP4 low temperature Sterilizer

The STERIZONE^® VP4 Sterilizer developed by TSO₃ is a dual sterilant, low temperature sterilization system that utilizes vaporized hydrogen peroxide (H₂O₂) and ozone. Its single cycle can sterilize a large number and wide range of compatible devices, thereby allowing for cost effective error-free sterilization process. TSO₃'s unique Dynamic Sterilant Delivery System^TM automatically adjusts the quantity of injected sterilant based on the load composition, weight and temperature. With its large 75-lb load capacity and a short cycle time, the STERIZONE^® VP4 Sterilizer can enhance throughput and lower sterilization cost. The STERIZONE^® VP4 Sterilizer was cleared for commercialization in the United States in December 2014.

More information about the STERIZONE^® VP4 Sterilizer is available through TSO₃'s website, under the Products section: http://www.tso3.com/en/products/sterizone-vp4/

About TSO₃

TSO₃'s activities encompass the sale, production, maintenance, research, development and licensing of sterilization processes, related consumable supplies and accessories for heat-sensitive medical devices. The Company designs products for sterile processing areas in the hospital environment that offer an advantageous replacement solution to other low temperature sterilization processes currently used in hospitals. It also offers services related to the maintenance of sterilization equipment and compatibility testing of medical devices with such processes.

For more information about TSO₃, visit the Company's Web site at www.tso3.com.

The statements in this release and oral statements made by representatives of TSO₃ relating to matters that are not historical facts (including, without limitation, those regarding the timing or outcome of any financing undertaken by TSO₃) are forward-looking statements that involve certain risks, uncertainties and hypotheses, including, but not limited to, general business and economic conditions, the condition of the financial markets, the ability of TSO₃ to obtain financing on favourable terms and other risks and uncertainties.

The TSX has neither approved nor disapproved the information contained herein and accepts no responsibility for it.

SOURCE TSO3 Inc.

R.M. (Ric) Rumble, President and CEO, [phone], Email: [email protected]; Paule De Blois, General Manager, Administration, [phone], Email: [email protected]